Causal Flows are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow, a mutation may causally activate or deactivate a downstream regulator which then might up- down-regulates a regulon that contains genes with similar expression profiles and binding sites.
Causal Mechanistic Flows regulated by Mutation NBAS_code_potential_somatic
| ID | Mutation | Role | Regulator | Role | Regulon | # downstream regulons | # diffexp regulons | Drugs |
|---|---|---|---|---|---|---|---|---|
| CMF-27068 | NBAS | up-regulates | PAX6 | activates | R-1294 | 16 | 3 | Drugs (5) Regulator Drugs (0)Regulon Drugs (5)ELIGLUSTAT, ELIGLUSTAT TARTRATE, MIGLUSTAT, SATRALIZUMAB, LUCERASTAT |
| CMF-27072 | NBAS | up-regulates | ZBTB16 | activates | R-2185 | 16 | 3 | Drugs (4) |
| CMF-27083 | NBAS | down-regulates | ELF5 | represses | R-3359 | 16 | 4 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-27091 | NBAS | up-regulates | TBP | activates | R-3475 | 18 | 3 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-27093 | NBAS | up-regulates | TBP | activates | R-3462 | 18 | 3 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-27097 | NBAS | up-regulates | EGR1 | activates | R-1003 | 20 | 4 | Drugs (11) Regulator Drugs (0)Regulon Drugs (11)BEVACIZUMAB, CONBERCEPT, PEGAPTANIB SODIUM, PEGAPTANIB OCTASODIUM, MUPARFOSTAT, VANUCIZUMAB, RANIBIZUMAB, FARICIMAB, ABICIPAR PEGOL, AFLIBERCEPT, BROLUCIZUMAB |
| CMF-27100 | NBAS | up-regulates | JUN | activates | R-225 | 25 | 3 | Drugs (0) Regulator Drugs (0)Regulon Drugs (0) |
| CMF-27108 | NBAS | up-regulates | CEBPG | activates | R-1048 | 23 | 2 | Drugs (13) Regulator Drugs (0)Regulon Drugs (13)OPROZOMIB, IXAZOMIB, PENTOXIFYLLINE, CAFFEINE, CITRATED, BORTEZOMIB, ETRUMADENANT, IXAZOMIB CITRATE, CAFFEINE, ADENOSINE, OXTRIPHYLLINE, THEOPHYLLINE, AMINOPHYLLINE, CARFILZOMIB |
| CMF-27109 | NBAS | up-regulates | CEBPG | activates | R-1038 | 23 | 2 | Drugs (5) |
| CMF-42275 | NBAS | down-regulates | hsa-mir-361 | represses | R-2202 | 14 | 4 | Drugs (5) Regulator Drugs (0)Regulon Drugs (5)ELIGLUSTAT, ELIGLUSTAT TARTRATE, MIGLUSTAT, SATRALIZUMAB, LUCERASTAT |
| CMF-42276 | NBAS | down-regulates | hsa-mir-361 | represses | R-378 | 14 | 4 | Drugs (7) Regulator Drugs (0)Regulon Drugs (7)DINOPROSTONE, BRODALUMAB, CR-6086, GRAPIPRANT, RIVENPROST, DIQUAFOSOL, DIQUAFOSOL TETRASODIUM |
| CMF-42277 | NBAS | down-regulates | hsa-mir-361 | represses | R-1510 | 14 | 4 | Drugs (16) Regulator Drugs (0)Regulon Drugs (16)PONEZUMAB, CRENEZUMAB, ELIGLUSTAT, GANTENERUMAB, SOLANEZUMAB, ELIGLUSTAT TARTRATE, MIGLUSTAT, BAPINEUZUMAB, GSK933776, SATRALIZUMAB, LUCERASTAT, ADUCANUMAB, TRAMIPROSATE, LECANEMAB, DONANEMAB, VANUTIDE CRIDIFICAR |
| CMF-42278 | NBAS | down-regulates | hsa-mir-361 | represses | R-3707 | 14 | 4 | Drugs (5) Regulator Drugs (0)Regulon Drugs (5)ELIGLUSTAT, ELIGLUSTAT TARTRATE, MIGLUSTAT, SATRALIZUMAB, LUCERASTAT |
| CMF-42279 | NBAS | down-regulates | hsa-mir-301 | represses | R-378 | 37 | 3 | Drugs (7) Regulator Drugs (0)Regulon Drugs (7)DINOPROSTONE, BRODALUMAB, CR-6086, GRAPIPRANT, RIVENPROST, DIQUAFOSOL, DIQUAFOSOL TETRASODIUM |
| CMF-42280 | NBAS | down-regulates | hsa-mir-301 | represses | R-572 | 37 | 3 | Drugs (11) Regulator Drugs (0)Regulon Drugs (11)SULTHIAME, CILENGITIDE, SENICAPOC, DKN-01, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, TOSEDOSTAT, BHQ-880, ABITUZUMAB |
| CMF-42281 | NBAS | down-regulates | hsa-mir-301 | represses | R-3010 | 37 | 3 | Drugs (9) Regulator Drugs (0)Regulon Drugs (9)SULTHIAME, CILENGITIDE, SENICAPOC, CG250 177LU, GIRENTUXIMAB, CG250 111IN, INTETUMUMAB, TOSEDOSTAT, ABITUZUMAB |
| CMF-42282 | NBAS | down-regulates | hsa-mir-197 | represses | R-1510 | 3 | 1 | Drugs (16) Regulator Drugs (0)Regulon Drugs (16)PONEZUMAB, CRENEZUMAB, ELIGLUSTAT, GANTENERUMAB, SOLANEZUMAB, ELIGLUSTAT TARTRATE, MIGLUSTAT, BAPINEUZUMAB, GSK933776, SATRALIZUMAB, LUCERASTAT, ADUCANUMAB, TRAMIPROSATE, LECANEMAB, DONANEMAB, VANUTIDE CRIDIFICAR |